The WATS3D test for Barrett's esophagus and dysplasia screening and surveillance has been selected for podium presentation at the 2025 Digestive Disease Week (DDW) in San Diego, the premier conference for gastroenterology professionals.

WATS3D, the company’s proprietary diagnostic platform leverages AI enabled tissue analysis and 3D imaging to identify precancerous cells in the esophagus

WATS3D enhances traditional forceps biopsy testing with an innovative brush sampling technique and AI assisted 3D imaging to detect abnormal cells that might otherwise go undetected.

The pivotal study highlighted WATS3D's significant impact on improving precancer detection during GERD screenings.

CDx Diagnostics, Inc., developer and provider of the WATS3D solution, today announces a substantial expansion in its insurance coverage network

CDx Diagnostics, Inc. today announced that it has received its 400,000th WATS3D specimen. WATS3D, the company’s proprietary diagnostic platform leverages AI enabled tissue analysis and 3D imaging to identify precancerous cells in the esophagus.

This was a collaborative study among gastrointestinal pathologists who have an interest and expertise in Barrett’s esophagus.

CDx Diagnostics, Inc., developer of the WATS3D AI Platform for the detection and surveillance of Barrett's esophagus (BE) and dysplasia, today announced the publication of a new study.